J Rheum Dis.
2012 Apr;19(2):67-72. 10.4078/jrd.2012.19.2.67.
B Cell Targeted Therapy in Rheumatic Disease
- Affiliations
-
- 1Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea. chsuh@ajou.ac.kr
- KMID: 2223103
- DOI: http://doi.org/10.4078/jrd.2012.19.2.67
Abstract
- B cells play an important role in the pathogenesis of autoimmune disease. B cells not only produce pathogenic autoantibodies, but also present self-antigens to T cells and provide costimulatory signals for self-reactiveT cells. Recently, biologics have been tried in several autoimmune diseases as immune modulators with some promising results. Among them, several biologic agents that target B cells have led to improved patients' outcomes and quality of life in patients with rheumatoid arthritis and systemic lupus erythematosus. These agents either deplete B cells by targeting B cell surface antigens, such as CD20 and CD22, or block B cell survival by inhibiting the activity of B cell survival factors, such as BLyS and APRIL. Initially, I discuss briefly the role of B cells in driving autoimmune diseases, and then focus on the efficacy and safety data of the B cell-targeted therapy in rheumatoid arthritis and systemic lupus erythematosus.
